%0 Case Reports
%T A case of relapsing anti-GBM disease secondary to alemtuzumab therapy.
%A Leibowitz SM
%A Manickam V
%A Srivastava V
%A Kan G
%J CEN Case Rep
%V 13
%N 3
%D 2024 Jun 9
%M 37943475
暂无%R 10.1007/s13730-023-00822-6
%X We report the first case of relapsing anti-GBM disease secondary to alemtuzumab in a 24-year-old female with relapsing-remitting multiple sclerosis. Initial anti-GBM disease was detected 10 months after alemtuzumab was given and was diagnosed by demonstrating high anti-GBM antibody titers and with a confirmatory kidney biopsy. The patient presented with a rapidly progressive glomerulonephritis with no pulmonary involvement. After appropriate treatment, the patient went into remission with undetectable anti-GBM antibodies. However, 20 months later, the patient re-presented with relapsing anti-GBM disease. Despite aggressive treatment, the patient became dialysis-dependent.